Duality Biotherapeutics (FRA:4ZB) Retained Earnings: €-744.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Retained Earnings?

Duality Biotherapeutics FRA:4ZB +6.49% 19 Retained Earnings is €-744.1 Mil as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Duality Biotherapeutics's retained earnings for the quarter that ended in Jun. 2026 was €-744.1 Mil.

Duality Biotherapeutics's quarterly retained earnings declined from Jun. 2025 (€-512.8 Mil) to Dec. 2025 (€-591.5 Mil) and declined from Dec. 2025 (€-591.5 Mil) to Jun. 2026 (€-744.1 Mil).

Duality Biotherapeutics's annual retained earnings declined from Dec. 2023 (€-147.5 Mil) to Dec. 2024 (€-297.1 Mil) and declined from Dec. 2024 (€-297.1 Mil) to Dec. 2025 (€-591.5 Mil).


Duality Biotherapeutics  (FRA:4ZB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Duality Biotherapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Retained Earnings Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Retained Earnings
-101.50 -147.53 -297.05 -591.52

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Retained Earnings -512.80 -591.52 -744.07
FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-744.1 Mil mean?
Duality Biotherapeutics (FRA:4ZB) has a Retained Earnings of €-744.1 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' Retained Earnings too high?
Duality Biotherapeutics' current Retained Earnings is €-744.1 Mil. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Retained Earnings compare to VRTX and REGN?
Duality Biotherapeutics' Retained Earnings of €-744.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Retained Earnings is €-744.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Retained Earnings of €-744.1 Mil. The current Retained Earnings is €-744.1 Mil. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Retained Earnings is €-744.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price